Rodgers & Associates LTD Has $201,000 Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Rodgers & Associates LTD trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.4% during the second quarter, HoldingsChannel.com reports. The fund owned 496 shares of the medical research company’s stock after selling 23 shares during the period. Rodgers & Associates LTD’s holdings in Thermo Fisher Scientific were worth $201,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of TMO. Brighton Jones LLC raised its holdings in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the period. GAMMA Investing LLC raised its holdings in Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after buying an additional 877 shares during the period. CWA Asset Management Group LLC raised its holdings in Thermo Fisher Scientific by 4.3% during the 1st quarter. CWA Asset Management Group LLC now owns 1,435 shares of the medical research company’s stock worth $714,000 after buying an additional 59 shares during the period. Finally, Premier Path Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 5.8% during the 1st quarter. Premier Path Wealth Partners LLC now owns 1,893 shares of the medical research company’s stock worth $942,000 after buying an additional 104 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last quarter. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $539.05 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a fifty day simple moving average of $495.74 and a 200 day simple moving average of $449.41. The stock has a market capitalization of $203.55 billion, a PE ratio of 31.18, a P/E/G ratio of 2.91 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. During the same period last year, the business earned $5.37 earnings per share. The firm’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on TMO. Barclays raised their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, October 12th. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $589.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.